Picture of Abbvie logo

ABBV Abbvie News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

REG - BkofA Merrill Lynch AbbVie Inc. - Form 38.5 (b) - AbbVie Inc




 



RNS Number : 1373M
Bank of America Merrill Lynch
06 May 2020
 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1.

KEY INFORMATION

Name of exempt principal trader

Bank of America, N.A., Proprietary

Company dealt in

AbbVie Inc

Class of relevant security to which the
dealings being disclosed relate(Note 1)

Common - US00287Y1091

Date of dealing

05/05/2020

 

2.

INTERESTS AND SHORT POSITIONS

(a)

Interests and short positions (following dealing) in the class of relevant security
dealt in (Note 2)

Class of relevant security: Common

US00287Y1091


Long

Short

Number

%

Number

%

(1)

Relevant securities

1,744,641

0.118%

2,660,806

0.18 %

(2)

Derivatives (other than options):

3,526,615

0.239%

2,737,226

0.185%

(3)

Options and agreements to purchase/sell:

0

0%

0

0%

Total

5,271,256

0.357%

5,398,032

0.366%

 

(b)

Interests and short positions in relevant securities of the company, other than the
class dealt in (Note 2)

Class of relevant security:



Long

Short

Number

%

Number

%

(1)

Relevant securities

0

0%

0

0%

(2)

Derivatives (other than options):

0

0%

0

0%

(3)

Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

3.

DEALINGS (Note 3)

(a)

Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Purchase

    21,626

 81.86 USD         

Purchase

            1

 83.35 USD         

Purchase

            1

 83.41 USD         

Purchase

            1

 83.46 USD         

Purchase

            1

 83.61 USD         

Purchase

            1

 83.62 USD         

Purchase

            1

 83.88 USD         

Purchase

            1

 83.91 USD         

Purchase

            1

 84.03 USD         

Purchase

            1

 84.19 USD         

Purchase

            1

 84.2 USD         

Purchase

            1

 84.29 USD         

Purchase

            1

 84.32 USD         

Purchase

            1

 84.34 USD         

Purchase

            1

 84.35 USD         

Purchase

            2

 84.39 USD         

Purchase

            1

 84.4 USD         

Purchase

            1

 84.43 USD         

Purchase

            1

 84.52 USD         

Purchase

            1

 84.53 USD         

Purchase

            1

 84.62 USD         

Purchase

            1

 84.63 USD         

Purchase

            1

 84.65 USD         

Purchase

            1

 84.71 USD         

Purchase

          23

 85.28 USD         

Purchase

          23

 85.3 USD         

Purchase

          59

 85.34 USD         

Purchase

     1,139

 85.37 USD         

Purchase

          96

 85.39 USD         

Purchase

          30

 85.41 USD         

Purchase

          83

 85.43 USD         

Purchase

          25

 85.46 USD         

Purchase

  161,399

 85.468 USD         

Purchase

          24

 85.47 USD         

 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Sale

   21,626

 81.86 USD         

 Sale

       286

 85.37 USD         

 

(b)

Derivatives transactions (other than options transactions)

Product name,
e.g. CFD

Nature of transaction
(Note 5)

Number of relevant securities
(Note 6)

Price per unit
(Note 4)

Swaps

Reducing a Long Position

142,890

85.37 USD

Swaps

Reducing a Long Position

21,946

86.236 USD

Swaps

Opening a Long Position

3,437

86.23 USD

 

(c)

Options transactions in respect of existing relevant securities

(i)

Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc

Expiry date

Option money paid/ received per unit (Note 4)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Product name,
e.g. call option

Number of securities

Exercise price per
unit
(Note 4)

N/A

N/A

N/A

 

(d)

Other dealings (including transactions in respect of new securities) (Note 3)

Nature or transaction
(Note 7)

Details

Price per unit
(if applicable)
(Note 4)

N/A

N/A

N/A

 

4.

OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.

None

 

Is a Supplemental Form 38.5(b) attached? (Note 8)

No

 

Date of disclosure

06/05/2020

Contact name

Tolu Tade

Telephone number

+44207 996 3410

Name of offeree/offeror with which connected

AbbVie Inc

Nature of connection (Note 9)

Advisor to - AbbVie Inc

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ISEBQLFBBELXBBF

Recent news on Abbvie

See all news